Modulation of murine breast tumor vascularity, hypoxia, and chemotherapeutic response by exercise

Journal of the National Cancer Institute

Volumn 107, Issue 5, 2015, Pages

  Betof, Allison S ^a,b   Lascola, Christopher D ^a   Weitzel, Douglas ^a   Landon, Chelsea ^a   Scarbrough, Peter M ^a   Devi, Gayathri R ^a   Palmer, Gregory ^a   Jones, Lee W ^c   Dewhirst, Mark W ^a  

^a DUKE CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ALKYLATING AGENT; ESTROGEN RECEPTOR;

AEROBIC EXERCISE; ANALYSIS OF COVARIANCE; ANALYSIS OF VARIANCE; APOPTOSIS; ARTICLE; BODY WEIGHT; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXERCISE; FEMALE; HOST RESISTANCE; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; KINESIOTHERAPY; LINEAR REGRESSION ANALYSIS; MAMMARY GLAND FAT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUMOR CELL INOCULATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL HYPOXIA; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZATION; STATISTICAL MODEL; TREATMENT OUTCOME; TUMOR CELL LINE; VASCULARIZATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; EXERCISE; FEMALE; HUMANS; LINEAR MODELS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICROCIRCULATION; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 84928419442     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv040     Document Type: Article

References (33)

1. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer. 2008;8(6):425-437.
2. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nature Rev Drug Discov. 2011;10(6):417-427.
3. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38-47.
4. Bottaro DP, Liotta LA. Cancer: Out of air is not out of action. Nature. 2003;423(6940):593-595.
5. DeClerck K, Elble RC. The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Fronti Biosci (Landmark Ed). 2010;15:213-225.
6. Kelleher DK, Mattheinsen U, Thews O, et al. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res. 1996;56(20):4728-4734.
7. Brizel DM, Lin S, Johnson JL, et al. The mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenation. Br J Cancer. 1995;72(5):1120-1124.
8. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 2000;60(16):4440-4445.
9. Jones LW, Hornsby WE, Goetzinger A, et al. Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer. 2012;76(2):248-252.
10. Overgaard J, Horsman MR. Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers. Semin Radiat Oncol. 1996;6(1):10-21.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med. 2004;350(23):2335-2342.
12. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 2008;26(12):2013-2019.
13. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227-1234.
14. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med. 2006;355(24):2542-2550.
15. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab vs paclitaxel alone for metastatic breast cancer. New Engl J Med. 2007;357(26):2666-2676.
16. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6(6):553-563.
17. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071-1121.
18. Jones LW, Viglianti BL, Tashjian JA, et al. Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer. J Applied Physiol. 2010;108(2):343-348.
19. Jones LW, Antonelli J, Masko EM, et al. Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. J Applied Physiol. 2012;113(2):263-272.
20. McCullough DJ, Stabley JN, Siemann DW, et al. Modulation of Blood Flow, Hypoxia, and Vascular Function in Orthotopic Prostate Tumors During Exercise. J Natl Cancer Inst. 2014;106(4).
21. Jones LW, Dewhirst MW. Therapeutic Properties of Aerobic Training After a Cancer Diagnosis: More Than a One-Trick Pony? J Natl Cancer Inst. 2014;106(4).
22. Secomb TW, Hsu R, Ong ET, et al. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncologica. 1995;34(3):313-316.
23. Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 1996;56(23):5522-5528.
24. Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther. 2006;5(10):2435-2443.
25. Betof AS, Dewhirst MW, Jones LW. Effects and Potential Mechanisms of Exercise Training on Cancer Progression: A Translational Perspective. Brain Behav Immun. 2013;30(Supplement):S75-S87.
26. Jones LW, Eves ND, Courneya KS, et al. Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts. Clinical Cancer Res. 2005;11(18):6695-6698.
27. Secomb TW, Hsu R, Dewhirst MW, et al. Analysis of oxygen transport to tumor tissue by microvascular networks. Int J Radiat Oncol Biol Phys. 1993;25(3):481-489.
28. Jones LW, Viglianti BL, Tashjian JA, et al. Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer. J Appl Physiol. 2010;108(2):343-348.
29. Kerbel RS. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J Mammary Gland Biol Neoplasia. 2012;17(3-4):229-239.
30. Holmes MD, Chen WY, Feskanich D, et al. Physical activity and survival after breast cancer diagnosis. JAMA. 2005;293(20):2479-2486.
31. Irwin ML, Smith AW, McTiernan A, et al. Influence of pre-and postdiagnosis physical activity on mortality in breast cancer survivors: The health, eating, activity, and lifestyle study. J Clin Oncol. 2008;26(24):3958-3964.
32. Jones LW, Fels DR, West M, et al. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res (Phila). 2013;6(9):925-937.
33. Courneya KS, Segal RJ, McKenzie DC, et al. Effects of Exercise during Adjuvant Chemotherapy on Breast Cancer Outcomes. Med Sci Sports Exerc. 2014;46(9):1744-1751.